NEW YORK (GenomeWeb News) – Accelr8 Technology’s fiscal first-quarter revenues plummeted to $8,304 from $202,008 a year ago, the company disclosed in a regulatory document today.

For the three months ended Oct. 31, the biggest year-over-year drop in revenues was in technical development fees due to the conclusion of certain programs last year. The firm had no revenues from such programs in the recently completed quarter compared to $140,000 a year ago, it said in a Form 10-Q filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.